Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Nirmatrelvir (PF-07321332) in Healthy Adults
NCT04756531Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2021
- Primary completion
- Sep 2021
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Pfizer. Primary endpoints: Treatment Emergent Adverse Events at 45 days, Clinically Significant Change From Baseline in Vital Signs at Day 5 and 6 more. Started Feb 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04756531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756531.